1. POTENTIAL IMPACT OF A NONAVALENT VACCINE ON HPV RELATED LOW-AND HIGH-GRADE CERVICAL INTRAEPITHELIAL LESIONS
- Author
-
Capra, G., Bellavia, C., Giovannelli, L., Caleca, M., Matranga, D., Pistoia, D., Perino, A., Capra, G, Bellavia, C, Giovannelli, L, Caleca, MP, Matranga, D, Pistoia,D, and Perino,A
- Subjects
human papillomavirus, HPV, vaccine, cervical intraepithelian lesions ,Settore MED/07 - Microbiologia E Microbiologia Clinica - Abstract
Introduction: Demonstration of the role of persistent infection, with high-risk (HR) human papillomaviruses (HPV) as the causal agent of cervical cancer made the development of first and second generation prophylactic vaccines. Bivalent and quadrivalent HPV vaccines are at the moment available in Europe. In 2014 is licensing a nonavalent HPV vaccine against HPV types: 6/11/16/18/31/33/45/52/58. The aim of our study was to evaluate the potential impact on HPV infection and related low- and high-grade cervical lesions (LSIL, HSIL) of the candidate nonavalent HPV vaccine, compared to the impact of the quadrivalent, in a female population living in Sicily. Materials and Methods: HPV genotypes was identified by Linear Array HPV Genotyping Test (Roche Diagnostics) and with the INNO-LiPA HPV assay (Innogenetics) for ambiguous HPV 52 status. Low estimates of HPV vaccine impact was calculated as prevalence of HPV 6/11/16/18/31/33/45/52/58 genotypes alone or in association but excluding presence of another HPV type; high estimate as prevalence of HPV 6/11/16/18/31/ 33/45/52/58 genotypes alone or in association, in presence of another HPV type. Results:1794 samples had a HPV positive finding. HR HPV types, alone or with LR types, were present in 1466 (81.7%) samples. 584/1794 (32.5%) samples harboured at least one of the four HPV types covered by the quadrivalent vaccine (HPV 6/11/16 and 18), while 984 (54.8%) samples harboured at least one of the genotypes included in nonavalent vaccine, implying a significantly higher estimated coverage of HPV infection from the developing vaccine than the current quadrivalent (54.8% vs 32.5%; p
- Published
- 2016